Anbio Biotechnology Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '21 Dec 31, 2021
Revenue	8.65	8.19	6.71	4.43
Revenue Growth (YoY)	5.64%	21.95%	51.57%	-
Cost of Revenue	1.1	2.3	3.35	1.89
Gross Profit	7.54	5.89	3.36	2.54
Selling, General & Admin	1.57	3.44	1.27	0.09
Research & Development	0.2	0.45	0.13	-
Total Operating Expenses	1.78	3.89	1.4	0.09
Operating Income	5.77	2	1.96	2.46
Interest Income	0.14	0.34	0.17	-
Other Non-Operating Income (Expense)	0.49	0.04	0.13	0.08
Total Non-Operating Income (Expense)	0.64	0.38	0.29	0.08
Pretax Income	6.4	2.37	2.25	2.54
Net Income	6.4	2.37	2.25	2.54
Net Income to Common	6.4	2.37	2.25	2.54
Net Income Growth	169.87%	5.29%	-11.13%	-
Shares Outstanding (Basic)	44	42	21	0
Shares Outstanding (Diluted)	44	42	21	0
Shares Change (YoY)	3.26%	97.30%	21435200.00%	-
EPS (Basic)	0.15	0.06	0.10	25358.00
EPS (Diluted)	0.15	0.06	0.10	25358.00
EPS Growth	162.50%	-46.67%	-100.00%	-
Free Cash Flow	-6.74	2.08	0.9	4.18
Free Cash Flow Growth	-	131.57%	-78.52%	-
Free Cash Flow Per Share	-0.15	0.05	0.04	41813.30
Gross Margin	87.24%	71.90%	50.07%	57.40%
Operating Margin	66.70%	24.38%	29.22%	55.46%
Profit Margin	74.06%	28.99%	33.58%	57.26%
FCF Margin	-77.94%	25.42%	13.38%	94.42%
EBITDA	5.77	2	1.97	2.46
EBITDA Margin	66.70%	24.38%	29.39%	55.46%
EBIT	5.77	2	1.96	2.46
EBIT Margin	66.70%	24.38%	29.22%	55.46%

SEC Filings: 10-K · 10-Q